Randall Schatzman - Bolt Biotherapeutics CEO Director
| BOLT Stock | USD 0.44 0.03 7.32% |
Insider
Randall Schatzman is CEO Director of Bolt Biotherapeutics
| Age | 69 |
| Address | 900 Chesapeake Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 665 9295 |
| Web | https://www.boltbio.com |
Randall Schatzman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Randall Schatzman against Bolt Biotherapeutics stock is an integral part of due diligence when investing in Bolt Biotherapeutics. Randall Schatzman insider activity provides valuable insight into whether Bolt Biotherapeutics is net buyers or sellers over its current business cycle. Note, Bolt Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bolt Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Randall Schatzman over a year ago Purchase by Randall Schatzman of 2500 shares of Bolt Biotherapeutics |
Bolt Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3176) % which means that it has lost $0.3176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6499) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2025. Return On Capital Employed is likely to drop to -0.52 in 2025. Non Current Liabilities Total is likely to gain to about 46.8 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2025.Bolt Biotherapeutics currently holds 20.22 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Bolt Biotherapeutics has a current ratio of 9.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bolt Biotherapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| James Brady | Spero Therapeutics | N/A | |
| Michele Anderson | Assembly Biosciences | N/A | |
| MBA MD | Spero Therapeutics | 44 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Dr IV | Assembly Biosciences | 53 | |
| Gary Hattersley | Nuvation Bio | 58 | |
| Satyavrat CFA | Spero Therapeutics | 52 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Solomon Langermann | NextCure | 66 | |
| Robert Coutts | Achilles Therapeutics PLC | 41 | |
| MD FACP | NextCure | 71 | |
| Sandeep MD | Instil Bio | 56 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Angela MD | Spero Therapeutics | N/A | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| CPA CPA | NextCure | 61 | |
| Christopher Ogden | CytomX Therapeutics | 41 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.32 |
Bolt Biotherapeutics Leadership Team
Elected by the shareholders, the Bolt Biotherapeutics' board of directors comprises two types of representatives: Bolt Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bolt. The board's role is to monitor Bolt Biotherapeutics' management team and ensure that shareholders' interests are well served. Bolt Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bolt Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randall Schatzman, CEO Director | ||
| William Quinn, CFO Secretary | ||
| Edith MD, Chief Officer | ||
| Michael Alonso, Senior Research | ||
| MBA CFA, Chief Officer | ||
| Ming Yin, VP Biometrics | ||
| Bruce MD, Sr Medicine | ||
| Edgar MD, Founder Director | ||
| Nathan Ihle, Senior Operations | ||
| PharmD BCOP, Senior Development | ||
| Wesley Burwell, VP Resources | ||
| Karen Bergman, VP Relations | ||
| Sarah Nemec, Senior Officer |
Bolt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bolt Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (14.41) % | ||||
| Current Valuation | (19.74 M) | ||||
| Shares Outstanding | 38.27 M | ||||
| Shares Owned By Insiders | 5.09 % | ||||
| Shares Owned By Institutions | 48.23 % | ||||
| Number Of Shares Shorted | 121.4 K | ||||
| Price To Earning | 36.55 X | ||||
| Price To Book | 0.22 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.